A 19-year-old Canadian man becomes the first human cured through prime gene editing after doctors corrected a rare genetic ...

Infants born with alternating hemiplegia of childhood (AHC) begin experiencing episodes of paralysis and seizures by the time they are a few months old, followed by developmental delays and ...

Keith Gottesdiener, MD, former president and CEO of Prime Medicine Prime Medicine is eliminating 25% of its workforce—about 50 jobs—in a restructuring that includes the company pivoting its prime ...

Scientists use a precise form of gene editing called prime editing to correct the most common genetic mutations that cause alternating hemiplegia of childhood, a rare and severe neurological disorder ...

Researchers at the Francis Crick Institute have demonstrated that a genetic method called "pooled prime editing" can screen hundreds of variants in a gene at once and identify which variants affect ...

Prime Medicine secures up to $24 million from the CF Foundation to advance Prime Editors for cystic fibrosis treatment. Prime Medicine, Inc. has announced an agreement with the Cystic Fibrosis ...

The CRISPR gene editing system holds tremendous promise. It has already revolutionized biomedical research by making gene editing a straightforward process. It involves using a guide RNA molecule that ...

Alternating hemiplegia of childhood (AHC) is a rare, one-in-a-million genetic disease that affects kids. Most cases are caused by mutations in the ATP1A3 gene. That gene makes an ATPase enzyme that is ...

Prime Medicine, Inc. (PRME) was able to release positive data in using its Prime Editing technology therapy PM359 to treat one patient with Chronic Granulomatous Disease [CGD]. The patient was noted ...

In a new study published in Nature, researchers from the Massachusetts Institute of Technology (MIT) showcased engineered prime editors with significantly lower rates of indel formation. “This paper ...

Forbes contributors publish independent expert analyses and insights. Juergen Eckhardt leads Bayer’s impact investment unit, Leaps by Bayer. Dr. David Liu, pictured with former lab members Holly Rees ...